https://orcid.org/0000-0002-4782-8003
Reader Comments
Post a new comment on this article
Post Your Discussion Comment
Please follow our guidelines for comments and review our competing interests policy. Comments that do not conform to our guidelines will be promptly removed and the user account disabled. The following must be avoided:
- Remarks that could be interpreted as allegations of misconduct
- Unsupported assertions or statements
- Inflammatory or insulting language
Thank You!
Thank you for taking the time to flag this posting; we review flagged postings on a regular basis.
closeAmendments
Posted by lkaps on 27 Apr 2021 at 17:52 GMT
Dear colleagues,
we would like to inform you of the following typos, which we have noticed after publication of our study (corrections are highlighted with quotation marks):
In the abstract:
The 28-days mortality in the ADVOS group was “42% (11/26)” and was not inferior to predicted “mortality” (predicted median 28-days mortality was 44%, IQR 30; 59)
In the results:
Despite both cohorts had comparable grade of liver failure (MELD- and CLIF-C ACLF score) and baseline characteristics (table 4), in the ADVOS treated cohort 11 of 25 “(44%)” patients died, while 15 of 25 “(60%)” patients in the HD treated cohort did not survived for 28-days mortality (figure 3). In addition, predicted “mortality” by the CLIF-C ACLF score was 44% (IQR 30; 59, table 2) in the ADVOS cohort, suggesting that ADVOS does not negatively impact survival.
In the discussion:
In a preliminary survival analysis, ADVOS showed non-inferiority in 28-days morality compared “to” a matched cohort treated with regular hemodialysis (11 vs. 15 patients “died”). Additionally, the 28-days mortality of our ADVOS patients “was equal to” the predicted “mortality” of the CLIF-C ACLF score (44 vs. “44%”).
We apologize that these mistakes have escaped our attention.
Kind regards
Julia Weinmann-Menke & Leonard Kaps